Glucocorticoids Disrupt Skeletal Angiogenesis Through Transrepression of NF-κB-Mediated Preosteoclast Pdgfb

Yi Peng1,2, Shan Lv2,3, Yusheng Li4

  • 1Department of Orthopedic Surgery, The Third Xiangya Hospital, Central South University, Changsha, China.

Insights

Glucocorticoids suppress platelet-derived growth factor-BB (PDGF-BB) in preosteoclasts, inhibiting blood vessel formation and causing bone loss and growth failure in young mice.

Area of Science:

  • Skeletal biology
  • Endocrinology
  • Vascular biology

Background:

  • Angiogenesis is crucial for skeletal development, closely linked with osteogenesis.
  • Glucocorticoids (GCs) impair bone vasculature, leading to osteoporosis and growth retardation.
  • The precise mechanisms of GC-induced angiogenesis suppression remain unclear.

Purpose of the Study:

  • To investigate how GCs affect platelet-derived growth factor-BB (PDGF-BB) synthesis in preosteoclasts (POCs).
  • To determine the relationship between GC-induced changes in PDGF-BB and type H vessel formation, bone mass, and growth.
  • To elucidate the molecular pathways involved in GC-mediated suppression of PDGF-BB and angiogenesis.

Main Methods:

  • Prednisolone treatment in young mice for varying durations.
  • Analysis of POC numbers, PDGF-BB levels, type H vessels, bone mass, and growth.
  • In vitro studies using POC cultures and endothelial cells, investigating the role of NF-κB and GR signaling.

Main Results:

  • Prednisolone reduced POC synthesis of PDGF-BB, decreased type H vessels, bone formation, bone mass, and bone length.
  • Excessive prednisolone inhibited PDGF-BB production and POC numbers in vitro.
  • GCs suppressed PDGF-BB transcription via transrepression of NF-κB binding to the Pdgfb promoter, mediated by the glucocorticoid receptor (GR).

Conclusions:

  • Glucocorticoids suppress PDGF-BB synthesis in preosteoclasts through GR/NF-κB transrepression.
  • This suppression inhibits type H vessel formation, leading to osteoporosis and growth failure.
  • Targeting this pathway may offer therapeutic strategies for GC-induced bone diseases.